DBNDD2: A Potential Drug Target and Biomarker (G55861)

Target Name: DBNDD2

NCBI ID: G55861

DBNDD2

DBNDD2: A Potential Drug Target and Biomarker

Dysbindin domain-containing protein 2 (ISOform A) is a protein that is expressed in various tissues and cells of the human body. It plays a crucial role in the development and maintenance of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and function. Unfortunately, DBNDD2 has also been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The search for new drug targets and biomarkers has led to the identification of DBNDD2 as a potential drug target and biomarker. In this article, we will explore the biology and potential drug targets of DBNDD2.

The Biology of DBNDD2

DBNDD2 is a member of the tight junction protein family, which includes other proteins such as DANPP1, DNPT1, and TJP1. These proteins are involved in the formation and maintenance of tight junctions, which are specialized structures that mediate the transfer of electrical signals between cells.

DBNDD2 is expressed in various tissues and cells of the human body, including the brain, heart, liver, and cervical uterus. It is also involved in several signaling pathways, including the TGF-β pathway and the Wnt pathway.

In addition to its role in cell signaling, DBNDD2 has also been linked to the development and progression of several diseases. For example, DBNDD2 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. It has also been associated with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Potential Drug Targets

The identification of DBNDD2 as a potential drug target has led to the development of several compounds that have been shown to interact with the protein. These compounds include small molecules, peptides, and antibodies.

One of the most promising compounds is a small molecule called 尾-actinin, which is a natural product that has been shown to interact with DBNDD2.尾-actinin has been shown to inhibit the activity of DBNDD2 and to promote the formation of tight junctions in cultured cells.

Another compound that has been shown to interact with DBNDD2 is a peptide called P13. P13 is a 13-amino acid peptide that contains several domains, including a secreted domain and a transmembrane domain. P13 has been shown to interact with DBNDD2 and to promote the formation of tight junctions in cultured cells.

In addition to these compounds, there are also several antibodies that have been shown to interact with DBNDD2. These antibodies include monoclonal antibodies (MAbs), which are laboratory-produced antibodies that are specific for a particular protein, and polyclonal antibodies (PCAs), which are antibodies that are produced by a single clone of cells.

Biomarkers

The potential use of DBNDD2 as a drug target and biomarker has led to the development of several biomarkers that can be used to monitor the progression of diseases associated with DBNDD2.

One of the most promising biomarkers is a protein called DNPT1, which is a component of the tight junction protein family and is expressed in various tissues and cells of the human body. DNPT1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer, and has been used as a biomarker for monitoring the progression of these diseases.

Another biomarker that has been developed is a protein called TJP1, which is also a component of the tight junction protein family and is expressed in various tissues and cells of the human body. TJP1 has

Protein Name: Dysbindin Domain Containing 2

Functions: May modulate the activity of casein kinase-1. Inhibits CSNK1D autophosphorylation (in vitro)

The "DBNDD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBNDD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets